We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 91.00 | 1.20 | 1.60 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/4/2024 | 12:00 | UKREG | OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry.. |
| 09/4/2024 | 00:00 | UKREG | OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to.. |
| 02/4/2024 | 12:00 | UKREG | OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry.. |
| 22/3/2024 | 11:00 | UKREG | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance.. |
| 21/3/2024 | 11:00 | UKREG | OKYO Pharma to Host Key Opinion Leader Event to Discuss New and.. |
| 20/3/2024 | 11:00 | UKREG | OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye.. |
| 09/2/2024 | 12:36 | IHNW | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal.. |
| 09/2/2024 | 12:00 | UKREG | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal.. |
| 31/1/2024 | 12:00 | UKREG | OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the.. |
| 22/5/2023 | 08:15 | UKREG | OKYO Pharma Limited London Stock Exchange Delisting |
1 Year Okyo Pharma Chart |
Intraday Okyo Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
